Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder <l ...

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Proficio Capital Partners LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during ...

Of the 103 patients who completed the Phase III trial, more than half saw remission from a drug-induced condition.

Time is running out to secure the lowest ticket prices for Yotta 2025, the premier event bringing together the entire digital ...

Planet Fitness, one of the largest and fastest-growing franchisors and operators of fitness centers with more members than any other fitness brand, is here to help everyone rebound and recover from ...

The FDA unveiled the Chemical Contaminants Transparency Tool, a searchable online database that provides a list of chemical contaminant types and levels used to evaluate possible harm in foods ...